Tirzepatide
The latest news about Tirzepatide: headlines, AI summaries and the full story from every source.
- Study Finds Weight-Loss Drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) Effective at Lower Doses
- Eli Lilly Reports Positive Clinical Trial Results for Tirzepatide
- Eli Lilly's Tirzepatide Shows Strong Results in New Clinical Trials
- Barclays Raises Price Target for Eli Lilly to $1,400 Amid Tirzepatide Momentum
- FDA Proposes Excluding Novo Nordisk and Eli Lilly Weight Loss Drugs from Bulk Compounding List